All In Biotech

Drug Trial Radar · NCT05559099

Tecovirimat for Treatment of Monkeypox Virus

A Randomized, Placebo-controlled, Double-blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Adult and Pediatric Patients With Monkeypox Virus Disease

Last checked: Nov 19, 2026Latest source record: Oct 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 597 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

597

Actual

Start

Oct 10, 2022

Primary completion

Sep 3, 2024

Study completion Sep 3, 2024

Sponsor

Sponsor type
NIH
Collaborators
Institut National de Recherche Biomedicale (INRB)
First posted
Sep 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out if tecovirimat is a safe and effective drug to treat monkeypox (mpox) in combination with standard of care (SOC). Participants will be randomly assigned to receive oral tecovirimat plus SOC or placebo plus SOC for 14 days.

Conditions

  • Monkeypox

Interventions

  • Tecovirimat Oral CapsuleDrug

    200 mg capsules Number of capsules and frequency of dosage will be based on participant weight: * ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg) * 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg) * 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg) * 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg) * 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg) * 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)

  • PlaceboDrug

    Capsules to match tecovirimat

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Lesion ResolutionTime frame: Up to day 28

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • L'Hôpital Général de Référence de Kole

    Kole, Democratic Republic of the Congo

  • L'Hôpital Général de Référence de Tunda

    Tunda, Democratic Republic of the Congo

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.